Many people with Parkinson’s disease eventually develop dyskinesias [dis-kuh-NEE-zhuhs] — abnormal and unwanted movements that are a side effect of the “gold standard” Parkinson’s disease treatment, levodopa. The severity of these movements can range from subtle to extremely debilitating, and for some people, dyskinesias interfere with everyday activities such as dressing or bathing.
Several clinical trials are studying the effectiveness of new therapies to treat dyskinesias. Here are just a few for your consideration:
EASED: Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia
While no therapy has been FDA-approved to treat dyskinesias, many physicians prescribe the Parkinson’s drug amantadine “off-label” based on anecdotal evidence. This trial is the first to rigorously evaluate the effectiveness of amantadine in reducing dyskinesias. This trial is taking place at several sites across the US. Review the trial listing to see if there is a site near you!
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
This trial is measuring the reduction of dyskinesias by amantadine (see above) and/or topiramate, an FDA-approved treatment for epilepsy. This trial is taking place at Oregon Health & Science University in Portland, Oregon. Review the trial listing for more information.
To ensure that you match to trials like these in the future, make sure your Fox Trial Finder profile is up-to-date with your medication history. Having this information completed in your profile is critical for coordinators for dyskinesia trials to determine whether you may qualify for a trial.